Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

When it comes to glioblastoma, the key isnt just the tumor its the immune system #shorts

12 Jan 2026 · 1 min

Watch on YouTube

0:57

In this short, the speaker outlines the typical clinical trajectory of glioblastoma multiforme (GBM): patients undergo maximal surgical resection, followed by radiation and temozolomide chemotherapy, often supplemented with additional radiation. Despite this aggressive multimodal regimen, recurrence commonly occurs within two years because GBM infiltrates the brain with finger‑like tentacles and many therapeutic agents cannot cross the blood‑brain barrier. The speaker argues that the limited durability of current treatments stems from a lack of focus on the tumor’s immune environment. To achieve lasting remission, future strategies must first understand and then target the immune context of each tumor, developing personalized, immune‑centric therapies.

Chapters

Imagine this. You had brain surgery to remove the tumor, then radiation plus temozolomide, even more radiation, and less than two years later, the tumor is back. Glioblastoma multiform GBM spreads like finger like shaped tentacles through the brain. Good drugs often can't reach it because of the blood brain barrier and that's why so many patients see a return. And when we see these patients with glioblastoma multiform and other brain cancers, it's so important to understand that the surgery oftentimes may not give us what we want. You know, maybe nine, 10 months, you go through surgery, it comes back, you add radiation and other spot treatment. You might get 18, 19 months, but it's still not enough because the treatment is not immune centric. The key is the immune system. So we understand the immune environment around these tumors and we can develop a custom treatment for these cancers to help them hold remission. That's the goal. And you know, it's not an easy goal, but it's the key to getting there is the immune system.